Recent Finacing
Recent Raise
Pierrepont Therapeutics develops targeted therapies for primary mitochondrial and other rare genetic diseases, advancing PTI-501, an intracellular enzyme-replacement therapy for MNGIE, under an exclusive license from Entrada.
